Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments

Core Insights - Amicus Therapeutics, Inc. (NASDAQ:FOLD) is recognized as one of the best biotech stocks under $20, primarily due to its innovative treatments for rare diseases [1] - Jefferies downgraded FOLD from Hold to Buy and reduced the price target from $16 to $14.50, reflecting a cautious outlook despite takeover interest [1][2] - BioMarin announced plans to acquire Amicus Therapeutics for $14.50 per share, valuing the company at approximately $4.8 billion, which includes two marketed therapies generating significant revenue [2] Company Overview - Amicus Therapeutics focuses on developing and commercializing treatments for rare and orphan diseases, with a pipeline that includes therapies for genetic and metabolic disorders such as Fabry disease [3] - The company leverages precision science and patient-centric solutions to enhance long-term health outcomes for patients [3] Financial Performance - The combined revenue from Amicus's marketed therapies, Galafold and Pombiliti + Opfolda, reached $599 million over the past four quarters, indicating strong market performance [2]